253 related articles for article (PubMed ID: 9498233)
1. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
Knoll J
Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
[TBL] [Abstract][Full Text] [Related]
2. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
3. (-)Deprenyl (Selegiline): past, present and future.
Knoll J
Neurobiology (Bp); 2000; 8(2):179-99. PubMed ID: 11061214
[TBL] [Abstract][Full Text] [Related]
4. (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
Knoll J
J Am Geriatr Soc; 1992 Aug; 40(8):839-47. PubMed ID: 1634730
[TBL] [Abstract][Full Text] [Related]
5. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
Knoll J
J Neural Transm Suppl; 1993; 40():69-91. PubMed ID: 8294902
[TBL] [Abstract][Full Text] [Related]
6. The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view.
Knoll J
Pharmacol Toxicol; 1992 May; 70(5 Pt 1):317-21. PubMed ID: 1608919
[TBL] [Abstract][Full Text] [Related]
7. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
Knoll J
Biomed Pharmacother; 1995; 49(4):187-95. PubMed ID: 7669938
[TBL] [Abstract][Full Text] [Related]
8. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
Miklya I
Mol Psychiatry; 2016 Nov; 21(11):1499-1503. PubMed ID: 27480491
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective actions of selegiline.
Ebadi M; Sharma S; Shavali S; El Refaey H
J Neurosci Res; 2002 Feb; 67(3):285-9. PubMed ID: 11813232
[TBL] [Abstract][Full Text] [Related]
10. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
Miklya I; Knoll B; Knoll J
Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases.
Knoll J
Med Res Rev; 1992 Sep; 12(5):505-24. PubMed ID: 1513186
[TBL] [Abstract][Full Text] [Related]
12. [Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal].
Miklya I
Neuropsychopharmacol Hung; 2009 Dec; 11(4):217-25. PubMed ID: 20150659
[TBL] [Abstract][Full Text] [Related]
13. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons.
Knoll J; Miklya I; Knoll B; Markó R; Kelemen K
Life Sci; 1996; 58(10):817-27. PubMed ID: 8602114
[TBL] [Abstract][Full Text] [Related]
14. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
Magyar K; Szende B
Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
[TBL] [Abstract][Full Text] [Related]
15. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
Miklya I
Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
[TBL] [Abstract][Full Text] [Related]
16. The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research.
Magyar K; Szende B; Lengyel J; Tekes K
J Neural Transm Suppl; 1996; 48():29-43. PubMed ID: 8988460
[TBL] [Abstract][Full Text] [Related]
17. Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: rationale for prophylactic (-)deprenyl (selegiline) medication.
Knoll J; Miklya I
Life Sci; 1995; 56(8):611-20. PubMed ID: 7869839
[TBL] [Abstract][Full Text] [Related]
18. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
Knoll J; Miklya I
Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
[TBL] [Abstract][Full Text] [Related]
19. Deprenyl (selegiline): the history of its development and pharmacological action.
Knoll J
Acta Neurol Scand Suppl; 1983; 95():57-80. PubMed ID: 6428148
[TBL] [Abstract][Full Text] [Related]
20. The neuroprotective and neuronal rescue effects of (-)-deprenyl.
Magyar K; Szende B; Lengyel J; Tarczali J; Szatmáry I
J Neural Transm Suppl; 1998; 52():109-23. PubMed ID: 9564614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
